One reason might be that Neurodegeneration did not manifest clinically for more than 10 years after the initial diagnosis of LCH (22) or due to the effective use of cytarabine and MARK pathway targeting therapy (23). This evidence concerns the gene MARK1 and Neurodegeneration.